GV20-0251 Clinical Trials
4 recruitingDrug
Phase 14Phase 22
Showing 1–4 of 4 trials
Recruiting
Phase 1
GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study
West China Hospital9 enrolled1 locationNCT07457281
Recruiting
Phase 1Phase 2
Study of GV20-0251 in Participants With Solid Tumor Malignancies
Solid Tumor CancerAdult Refractory CancerEndometrial Carcinoma (EC)+2 more
GV20 Therapeutics350 enrolled3 locationsNCT07070518
Recruiting
Phase 1
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
Endometrial CancerCholangiocarcinomaMelanoma+5 more
West China Hospital10 enrolled1 locationNCT07106827
Recruiting
Phase 1Phase 2
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Solid Tumor, AdultCutaneous MelanomaRefractory Cancer+3 more
GV20 Therapeutics365 enrolled13 locationsNCT05669430